Skip to content
Head to head

Relay Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RLAY · VRTX

Updated 6 minutes ago

1-year performance, rebased to 100

RLAY +143.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
RLAYVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price16.12515.02
Change today+1.32%-1.08%
1-year return+152.7%+22.0%
Market cap$3.56B$130.58B
52-week range6.80 – 21.27412.27 – 568.67
Valuation
P/E (TTM)-10.7533.14
P/E percentile, own 5-yr range4th99th
P/B4.356.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.6115.32
Net profit (TTM)$-355.74M$3.88B
Revenue (TTM)$10.35M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-3094.6%33.1%
Net margin-2837.0%30.7%
Free cash flow (TTM)$-214.02M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership126.1%96.8%
Insider activity (12mo)13 buy / 37 sell28 buy / 22 sell
Short interest (% of float)19.9%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$29 (+80%)$624 (+21%)
StockVane view
StockVane Quant RatingC (99)C (68)
Company
Employees1926,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.